ArticleScientific reports2026
m6A modification-mediated lncRNA UNC5B-AS1 enhances HCC progression through miR-760/IL6 axis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
WT1-associated protein (WTAP)-catalyzed m6A methylation drives oncogenic processes in HCC. Long noncoding RNA UNC5B-AS1 are associated with various types of cancer including hepatocellular carcinoma (HCC). Previous study indicated that UNC5B-AS1 promotes HCC progression. However, the precise roles of WTAP/UNC5B-AS1 axis in HCC progression remain unclear. In this study, we found that the m6A modification sites are highly abundant on UNC5B-AS1, and methylase WTAP enhances UNC5B-AS1 stability through m6A reader-YTHDF1 and up-regulates its expression in HCC. Functional tests showed that WTAP/UNC5B-AS1 axis drives HCC progression. Mechanically, UNC5B-AS1 acts as a molecular sponge to hsa-miR-760, to up-regulate the expression of Interleukin-6 (IL6), and plays a role in enhancing HCC progression. Our study reveals a mechanism by which m6A-RNA regulates oncogene activity, which might result in the creation of a therapeutic strategy for the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.